

10/10/2002  
L.D.S.

PTO/SB/08A(10-01)  
Approved for use through 10/31/2002, OMB 6510-033  
US Patent & Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <small>(Use as many sheets as necessary)</small>		Complete if Known				
		Application Number	09/993333			
		Filing Date	November 14, 2001			
		First Named Inventor	Oberley, Larry			
		Group Art Unit	1645			
		Examiner Name	Schultz, James			
Sheet 1 of 1		Attorney Docket No: 00875.042US1				

### US PATENT DOCUMENTS

Examiner Initials*	USP Document Number	Publication Date	Name of Patentee or Applicant of cited Document	Class	Subclass	Filing Date If Appropriate
--------------------	---------------------	------------------	---	-------	----------	----------------------------

### FOREIGN PATENT DOCUMENTS

Examiner Initials*	Foreign Document No	Publication Date	Name of Patentee or Applicant of cited Document	Class	Subclass	T <sup>2</sup>
--------------------	---------------------	------------------	---	-------	----------	----------------

### OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		AMSTAD, P., et al., "Genetic Modulation of the Cellular Antioxidant Defense Capacity", <u>Environmental Health Perspectives</u> , 88, (1990), 77-82	
		CLEMENT, M., et al., "Apoptosis Induced by Hydrogen Peroxide is Mediated by Decreased Superoxide Anion Concentration and Reduction of Intracellular Milieu", <u>FEBS Letters</u> , 440, (1998), 13-18	
		HIROSE, K., et al., "Overexpression of Mitochondrial Manganese Superoxide Dismutase Promotes the Survival of Tumor Cells Exposed to Interleukin-1, Tumor Necrosis Factor, Selected Anticancer Drugs, and Ionizing Radiation", <u>FASEB Journal</u> , 7, (1993), 361-368	
		PERVAIZ, S., et al., "Superoxide Anion Inhibits Drug-induced Tumor Cell Death", <u>FEBS Letters</u> , 459, (1999), 343-348	
		WONG, G.H., et al., "Manganous Superoxide Dismutase Is Essential for Cellular Resistance to Cytotoxicity of Tumor Necrosis Factor", <u>Cell</u> , 58, (Sep. 8, 1989), 923-931	

RECEIVED

OCT 24 2002

TECH CENTER 1600/2900

EXAMINER

DATE CONSIDERED

Substitute Disclosure Statement Form (PTO-1449)

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.<sup>1</sup> Applicant's unique citation designation number (optional) <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached



S/N 09/993,333

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Larry Wayne Oberley et al.

Examiner: James Schultz

Serial No.: 09/993,333

Group Art Unit: 1635

Filed: November 14, 2001

Docket: 875.042US1

Title: REDUCTION OF ANTIOXIDANT ENZYME LEVELS IN TUMOR CELLS  
USING ANTISENSE OLIGONUCLEOTIDES

#10/R.T.  
10/28  
Suppl.  
T.D.S

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents  
Washington, D.C. 20231

In compliance with the duty imposed by 37 C.F.R. § 1.56, and in accordance with 37 C.F.R. §§ 1.97 *et. seq.*, the enclosed materials are brought to the attention of the Examiner for consideration in connection with the above-identified patent application. Applicants respectfully request that this Supplemental Information Disclosure Statement be entered and the documents listed on the attached Form 1449 be considered by the Examiner and made of record. Pursuant to the provisions of MPEP 609, Applicants request that a copy of the 1449 form, initialed as being considered by the Examiner, be returned to the Applicants with the next official communication.

Pursuant to 37 C.F.R. §1.97(c)(1) and 37 C.F.R. §1.97(e)(1), Applicants state that each item of information contained in the Supplemental Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the Supplemental Information Disclosure Statement.

The references listed on the attached Form 1449 were cited in an International Search Report mailed August 13, 2002 in a co-pending PCT application. A copy of the ISR is attached hereto.

It is believed that no fee or statement is required with the Supplemental Information Disclosure Statement. However, if a final action under §1.113, a notice of allowance under §1.311, or an action that otherwise closes prosecution in the application has been mailed, the Commissioner is hereby authorized to charge the required fees to Account No. 19-0743 in order to have this Supplemental Information Disclosure Statement considered.

RECEIVED

OCT 24 2002

TECH CENTER 1600/2900